Benny Evison

Benny Evison Ph.D

Chief Scientific Officer

B. Sc. (Med. Sci.) (Hons); PhD

Dr. Benny Evison completed his B. Sc. (Med. Sci.) (Hons) in 2001 and commenced his PhD studies in 2002 at La Trobe University (LTU), Melbourne, Australia. During his PhD at LTU (2002–2007), he gained extensive research experience in the design, development, and analysis of novel DNA-directed therapeutic agents for the treatment of cancer, particularly breast and prostate cancers and lymphomas.

Dr. Evison was appointed as a postdoctoral research fellow in the School of Molecular Sciences, LTU in 2008 where he continued his research in the development of improved anticancer drugs and mentored students at both Honours and PhD levels. He subsequently moved to world-renowned St. Jude Children’s Research Hospital, Memphis, TN, USA, to commence a second postdoctoral research fellowship (2011-2017) where he was involved in the discovery and development of novel inhibitors of DNA repair for the chemosensitisation of paediatric cancers to existing DNA damage based therapies.

In 2017, Dr. Evison returned home to Australia to begin his current post at Nyrada Inc. where he hopes to leverage his extensive scientific experience to generate novel therapeutic entities for the treatment of human diseases.